117 related articles for article (PubMed ID: 38657366)
1. A validated LC-MS/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients.
Knight W; Margaryan T; Sanai N; Tovmasyan A
J Pharm Biomed Anal; 2024 Aug; 245():116150. PubMed ID: 38657366
[TBL] [Abstract][Full Text] [Related]
2. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH
Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors.
Jiang J; Bao X; Yue Y; Schiff D; Bindra R; Li J
Biomed Chromatogr; 2022 Dec; 36(12):e5478. PubMed ID: 35938683
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Rosing H; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1040():14-21. PubMed ID: 27898364
[TBL] [Abstract][Full Text] [Related]
5. Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry.
Bao X; Wu J; Sanai N; Li J
J Pharm Biomed Anal; 2019 Mar; 166():197-204. PubMed ID: 30660034
[TBL] [Abstract][Full Text] [Related]
6. Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging.
Morosi L; Matteo C; Ceruti T; Giordano S; Ponzo M; Frapolli R; Zucchetti M; Davoli E; D'Incalci M; Ubezio P
Int J Biol Sci; 2020; 16(8):1363-1375. PubMed ID: 32210725
[No Abstract] [Full Text] [Related]
7. Development and validation of a sensitive LC-MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients.
Wei Y; Liang H; Liu S; Guan S; Ma K; Guan Y; Chen Y; Huang M; Wang X; Lan C
J Pharm Biomed Anal; 2024 Jan; 237():115758. PubMed ID: 37832476
[TBL] [Abstract][Full Text] [Related]
8. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
Moore K; Zhang ZY; Agarwal S; Burris H; Patel MR; Kansra V
Cancer Chemother Pharmacol; 2018 Mar; 81(3):497-503. PubMed ID: 29322231
[TBL] [Abstract][Full Text] [Related]
9. An aqueous normal-phase chromatography coupled with tandem mass spectrometry method for determining unbound brain-to-plasma concentration ratio of AZD1775, a Wee1 kinase inhibitor, in patients with glioblastoma.
Wu J; Sanai N; Bao X; LoRusso P; Li J
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():25-32. PubMed ID: 27318641
[TBL] [Abstract][Full Text] [Related]
10. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
11. Human mass balance study and metabolite profiling of
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
[TBL] [Abstract][Full Text] [Related]
12. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
13. Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
Bai F; Johnson J; Wang F; Yang L; Broniscer A; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(25):2561-6. PubMed ID: 21803003
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS.
Margaryan T; Elliott M; Sanai N; Tovmasyan A
J Pharm Anal; 2022 Aug; 12(4):601-609. PubMed ID: 36105156
[TBL] [Abstract][Full Text] [Related]
15. Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).
Roberts MS; Turner DC; Owens TS; Ramachandran A; Wetmore C; Throm SL; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jun; 929():1-5. PubMed ID: 23644495
[TBL] [Abstract][Full Text] [Related]
16. Determination of unbound fraction of dorzagliatin in human plasma by equilibrium dialysis and LC-MS/MS and its application to a clinical pharmacokinetic study.
Yang R; Ren S; Jin X; Sun Y; Dong Y; Zhang J; Liang W; Chen L
J Pharm Biomed Anal; 2021 Feb; 195():113854. PubMed ID: 33388639
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of High-Throughput Bioanalytical Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Quantification of Newly Synthesized Antitumor Carbonic Anhydrase Inhibitors in Human Plasma.
Abdel-Megied AM; Eldehna WM; Abdelrahman MA; Elbarbry FA
Molecules; 2020 Dec; 25(23):. PubMed ID: 33291270
[TBL] [Abstract][Full Text] [Related]
18. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
19. Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).
Minocha M; Khurana V; Mitra AK
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jul; 901():85-92. PubMed ID: 22749591
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
